Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option

Nav: ₹ 559.2785 ↑ 1.05%
[as on 1 October, 2025]

Nav chart with SMA (Simple moving average) overlay

SMA (Simple Moving Average)

  • 100 SMA
  • 200 SMA
  • 300 SMA
  • 400 SMA
  • 500 SMA

Returns

NameYTD1D1W1M3M1Y3Y5Y7Y10Y
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option -4.68% 1.05% 1.05% -1.49% -2.91% -3.17% 22.19% 18.26% 18.93% 13.45%

Portfolio

Asset allocation

EquityDebtRealestateCommoditiesCash & Equivalents
99.46% 0.00% (Arbitrage: 0.00%) 0.00% 0.00% 0.54%

Equity

NameSectorWeight %
Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology11.94%
Divi's Laboratories LimitedPharmaceuticals & Biotechnology7.34%
Cipla LimitedPharmaceuticals & Biotechnology6.09%
Lupin LimitedPharmaceuticals & Biotechnology6.09%
Apollo Hospitals Enterprise LimitedHealthcare Services5.91%
Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology5.90%
MedPlus Health Services LimitedRetailing3.65%
Vijaya Diagnostic Centre LimitedHealthcare Services3.48%
GlaxoSmithKline Pharmaceuticals LimitedPharmaceuticals & Biotechnology3.04%
Gland Pharma LimitedPharmaceuticals & Biotechnology2.96%
Ajanta Pharma LimitedPharmaceuticals & Biotechnology2.84%
Thyrocare Technologies LimitedHealthcare Services2.63%
Abbott India LimitedPharmaceuticals & Biotechnology2.59%
Sai Life Sciences LimitedPharmaceuticals & Biotechnology2.52%
Dr. Lal Path Labs LimitedHealthcare Services2.41%
Zydus Lifesciences LimitedPharmaceuticals & Biotechnology2.35%
Mankind Pharma LimitedPharmaceuticals & Biotechnology2.24%
Narayana Hrudayalaya LimitedHealthcare Services2.16%
Aurobindo Pharma LimitedPharmaceuticals & Biotechnology2.09%
JB Chemicals & Pharmaceuticals LimitedPharmaceuticals & Biotechnology2.06%
Alkem Laboratories LimitedPharmaceuticals & Biotechnology2.05%
Pfizer LimitedPharmaceuticals & Biotechnology1.96%
Biocon LimitedPharmaceuticals & Biotechnology1.76%
Sanofi India LimitedPharmaceuticals & Biotechnology1.42%
Suraksha Diagnostic LimitedHealthcare Services1.39%
Sanofi Consumer Healthcare India LimitedPharmaceuticals & Biotechnology1.33%
IPCA Laboratories LimitedPharmaceuticals & Biotechnology1.30%
Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology1.29%
Fortis Healthcare LimitedHealthcare Services1.20%
Anthem Biosciences LimitedPharmaceuticals & Biotechnology1.04%
Syngene International LimitedHealthcare Services0.96%
Akums Drugs and Pharmaceuticals LimitedPharmaceuticals & Biotechnology0.82%
Emcure Pharmaceuticals LimitedPharmaceuticals & Biotechnology0.78%
AstraZeneca Pharma India LimitedPharmaceuticals & Biotechnology0.63%
Indoco Remedies LimitedPharmaceuticals & Biotechnology0.59%
Orchid Pharma LimitedPharmaceuticals & Biotechnology0.43%
Concord Biotech LimitedPharmaceuticals & Biotechnology0.22%

FAQ (Frequently asked questions)

  • What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 559.2785 as on 1 October, 2025.
  • What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are -4.68% as on 1 October, 2025.
  • What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are -3.17% as on 1 October, 2025.
  • What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 22.19% as on 1 October, 2025.
  • What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 18.26% as on 1 October, 2025.
  • What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 18.26% as on 1 October, 2025.